RETRACTED ARTICLE: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy
Open accessAbstract
Rationale: MDMA-assisted psychotherapy is under investigation as a novel treatment for posttraumatic stress disorder (PTSD). The primary mechanism of action of MDMA involves the same reuptake transporters targeted by antidepressant medications commonly prescribed for PTSD. Objectives: Data were pooled from four phase 2 trials of MDMA-assisted psychotherapy. To explore the effect of tapering antidepressant medications, participants who had been randomized to receive active doses of MDMA (75–125 mg) were divided into two groups (taper group (n = 16) or non-taper group (n = 34)). Methods: Between-group comparisons were made for PTSD and depression symptom severity at the baseline and the primary endpoint, and for peak vital signs across two MDMA sessions. Results: Demographics, baseline PTSD, and depression severity were similar between the taper and non-taper groups. At the primary endpoint, the non-taper group (mean = 45.7, SD = 27.17) had a significantly (p = 0.009) lower CAPS-IV total scores compared to the taper group (mean = 70.3, SD = 33.60). More participants in the non-taper group (63.6%) no longer met PTSD criteria at the primary endpoint than those in the taper group (25.0%). The non-taper group (mean = 12.7, SD = 10.17) had lower depression symptom severity scores (p = 0.010) compared to the taper group (mean = 22.6, SD = 16.69). There were significant differences between groups in peak systolic blood pressure (p = 0.043) and diastolic blood pressure (p = 0.032). Conclusions: Recent exposure to antidepressant drugs that target reuptake transporters may reduce treatment response to MDMA-assisted psychotherapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The effect size of 0.91 demonstrated in this study between MDMA-assisted therapy and placebo with therapy was larger than that for any other previously identified PTSD pharmacotherapy.
“By contrast, the effect size of 0.91 demonstrated in this study between MDMA-assisted therapy and placebo with therapy was larger than that for any other previously identified PTSD pharmacotherapy16–18.”
From MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (2021) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05249-5 · Cited by 359 · see citing works
RetractedJournal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,703 · see citing works
Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients
Beck, A. T., Steer, R. A., Ball, R., & Ranieri, W. F. (1996) · Journal of Personality Assessment · doi:10.1207/s15327752jpa6703_13 · Cited by 5,965 · see citing works
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024 · cited 1× · see citing works
“The CAPS-IV is a semi-structured interview addressing PTSD symptom clusters recognized by the DSM-IV (re-experiencing, avoidance, and hyperarousal) (Blake et al. 1995; Nagy et al. 1993; Weathers et al. 2001).”
BackgroundCombat Duty in Iraq and Afghanistan, Mental Health Problems, and Barriers to Care
Hoge, C. W., Castro, C. A., Messer, S. C., McGurk, D., Cotting, D. I., & Koffman, R. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040603 · Cited by 4,778 · see citing works
Clinician-administered PTSD scale: A review of the first ten years of research
Weathers, F. W., Keane, T. M., & Davidson, J. R. T. (2001) · Depression and Anxiety · doi:10.1002/da.1029 · Cited by 1,903 · see citing works
Posttraumatic stress disorder in the world mental health surveys
Koenen, K. C., Ratanatharathorn, A., Ng, L., McLaughlin, K. A., Bromet, E. J., Stein, D. J., Karam, E. G., Meron Ruscio, A., Benjet, C., Scott, K., et al. (2017) · Psychological Medicine · doi:10.1017/s0033291717000708 · Cited by 1,453 · see citing works
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674 · see citing works
Sareen, J., Cox, B. J., Stein, M. B., Afifi, T. O., Fleet, C., & Asmundson, G. J. G. (2007) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31803146d8 · Cited by 541 · see citing works
Mechanism of action of serotonin selective reuptake inhibitors
Stahl, S. M. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00221-3 · Cited by 540 · cited 1× · see citing works
“…of antidepressants are present only after weeks of daily dosing, involvement of several mechanisms has been posited, such as effects on downstream gene transcription, synaptogenesis , inflammation, and the hypothalamic-pituitary-adrenal axis (Malberg and Schechter 2005; Stahl 1998; Walker 2013).”
BackgroundMeyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · see citing works
Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30135-4 · Cited by 439 · see citing works
Self-citationOehen, P., Traber, R., Widmer, V., & Schnyder, U. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112464827 · Cited by 402 · see citing works
MDMA enhances emotional empathy and prosocial behavior
Hysek, C. M., Schmid, Y., Simmler, L. D., Domes, G., Heinrichs, M., Eisenegger, C., Preller, K. H., Quednow, B. B., & Liechti, M. E. (2014) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nst161 · Cited by 356 · see citing works
Benmansour, S., Cecchi, M., Morilak, D. A., Gerhardt, G. A., Javors, M. A., Gould, G. G., & Frazer, A. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-23-10494.1999 · Cited by 337 · see citing works
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280 · see citing works
Danforth, A. L., Grob, C. S., Struble, C., Feduccia, A. A., Walker, N., Jerome, L., Yazar-Klosinski, B., & Emerson, A. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5010-9 · Cited by 280 · see citing works
Self-citationLiechti, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00148-7 · Cited by 248 · see citing works
Dumont, G. J. H., Sweep, F. C. G. J., van der Steen, R., Hermsen, R., Donders, A. R. T., Touw, D. J., van Gerven, J. M. A., Buitelaar, J. K., & Verkes, R. J. (2009) · Social Neuroscience · doi:10.1080/17470910802649470 · Cited by 238 · see citing works
Liechti, M. E., & Vollenweider, F. X. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.348 · Cited by 236 · see citing works
Marcela Ot’alora, G., Grigsby, J., Poulter, B., Derveer, J. W. V., Giron, S. G., Jerome, L., Feduccia, A. A., Hamilton, S., Yazar‐Klosinski, B., Emerson, A., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118806297 · Cited by 233 · see citing works
Self-citationMeyer, J. H., Kapur, S., Eisfeld, B., Brown, G. M., Houle, S., DaSilva, J., Wilson, A. A., Rafi-Tari, S., Mayberg, H. S., & Kennedy, S. H. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.78 · Cited by 231 · see citing works
Pharmacology of antidepressants
Richelson, E. (2001) · Mayo Clinic Proceedings · doi:10.4065/76.5.511 · Cited by 210 · cited 1× · see citing works
“In addition, long-term administration of SSRIs desensitizes and downregulates 5-HT1A autoreceptors, leading to reduced negative feedback and ultimately more 5- HT released into the synapse (Richelson 2001).”
BackgroundWalker, F. R. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.10.002 · Cited by 175 · cited 1× · see citing works
“…of antidepressants are present only after weeks of daily dosing, involvement of several mechanisms has been posited, such as effects on downstream gene transcription, synaptogenesis , inflammation, and the hypothalamic-pituitary-adrenal axis (Malberg and Schechter 2005; Stahl 1998; Walker 2013).”
BackgroundGrob, C. S., Poland, R. E., Chang, L., & Ernst, T. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00078-2 · Cited by 175 · see citing works
Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs
Malberg, J., & Schechter, L. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053382223 · Cited by 167 · see citing works
MDMA enhances “mind reading” of positive emotions and impairs “mind reading” of negative emotions
Hysek, C. M., Domes, G., & Liechti, M. E. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2645-9 · Cited by 144 · cited 1× · see citing works
“MDMA enhances release of both oxytocin and ACTH (Dumont et al. 2009; Grob et al. 1996; Hysek et al. 2012).”
BackgroundShea, M. T., Vujanovic, A. A., Mansfield, A. K., Sevin, E., & Liu, F. (2010) · Journal of Traumatic Stress · doi:10.1002/jts.20497 · Cited by 139 · cited 1× · see citing works
“People with PTSD can face reduced quality of life in multiple areas, from workplace productivity to interpersonal relationships, and are at increased risk for suicidal thoughts or behavior (Sareen et al. 2007; Shea et al. 2010).”
BackgroundFarré, M., Abanades, S., Roset, P. N., Peiró, A. M., Torrens, M., O'Mathúna, B., Segura, M., & de la Torre, R. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.129056 · Cited by 113 · see citing works
Open Prospective Trial of Fluoxetine for Posttraumatic Stress Disorder
Nagy, L. M., Morgan, C. A., Southwick, S. M., & Charney, D. S. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199304000-00004 · Cited by 102 · cited 1× · see citing works
“The CAPS-IV is a semi-structured interview addressing PTSD symptom clusters recognized by the DSM-IV (re-experiencing, avoidance, and hyperarousal) (Blake et al. 1995; Nagy et al. 1993; Weathers et al. 2001).”
Background(1987) · PubMed · Cited by 88 · see citing works
Haahr, M. E., Fisher, P. M., Jensen, C. G., Frokjaer, V. G., Mahon, B. M., Madsen, K., Baaré, W. F. C., Lehel, S., Norremolle, A., Rabiner, E. A., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.147 · Cited by 86 · see citing works
Prosocial effects of MDMA: A measure of generosity
Kirkpatrick, M. G., Delton, A. W., Robertson, T. E., & de Wit, H. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115573806 · Cited by 85 · see citing works
Baldinger, P., Kranz, G. S., Haeusler, D., Savli, M., Spies, M., Philippe, C., Hahn, A., Höflich, A., Wadsak, W., Mitterhauser, M., et al. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.10.002 · Cited by 67 · see citing works
Effects of MDMA on body temperature in humans
Liechti, M. E. (2014) · Temperature · doi:10.4161/23328940.2014.955433 · Cited by 65 · cited 1× · see citing works
“MDMA-stimulated elevations in body temperature are partially dependent on norepinephrine and possibly serotonin (Liechti 2014), although the exact contribution of each transmitter remains unclear.”
BackgroundHagino, Y., Takamatsu, Y., Yamamoto, H., Iwamura, T., Murphy, D. L., Uhl, G. R., Sora, I., & Ikeda, K. (2011) · Current Neuropharmacology · doi:10.2174/157015911795017254 · Cited by 60 · see citing works
Hysek, C. M., & Liechti, M. E. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2761-6 · Cited by 58 · cited 2× · see citing works
“When MDMA is co-administered with a reuptake inhibitor such as citalopram or fluoxetine, the subjective and psychological effects are markedly attenuated (Farre et al. 2007; Hysek and Liechti 2012; Liechti et al. 2000).”
BackgroundRaap, D. K., García, F., Muma, N. A., Wolf, W. A., Battaglia, G., & de Kar, L. D. V. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37990-x · Cited by 46 · cited 1× · see citing works
“Two days post-treatment, 5-HT 1A mediated release of ACTH and oxytocin was reduced by 68 – 74% compared to placebo controls, and 60 days post-discontinuation, oxytocin response was reduced by 26% (Raap et al. 1999).”
BackgroundOlver, J. S., Burrows, G. D., & Norman, T. R. (1999) · CNS Drugs · doi:10.2165/00023210-199912030-00001 · Cited by 22 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G., M., Garas, W., Paleos, C., Gorman, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01336-3 · Cited by 1,004 · see citing works
Self-citationBecker, A. M., Holze, F., Grandinetti, T., Klaiber, A., Toedtli, V. E., Kolaczynska, K. E., Duthaler, U., Varghese, N., Eckert, A., Grünblatt, E., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2487 · Cited by 184 · see citing works
Yao, Y., Guo, D., Lu, T., Liu, F.-L., Huang, S., Diao, M.-Q., Li, S., Zhang, X.-J., Kosten, T. R., Shi, J., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115886 · Cited by 149 · see citing works
“…et al., 2021, 2018, 2016a; D ’ Souza et al., 2022; Danforth et al., 2018; Davis et al., 2021; Daws et al., 2022; Dos Santos et al., 2021; Feduccia et al., 2021; Gasser et al., 2014, ; 2015; Giovannetti et al., 2020; Goodwin et al., 2022; G.M. Goodwin et al., 2023a, 2023b; Gorman et al.,…”
Serotonin toxicity of serotonergic psychedelics
Malcolm, B., & Thomas, K. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05876-x · Cited by 138 · see citing works
MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G, M., Garas, W., Paleos, C., Gorman, I., et al. (2023) · Focus · doi:10.1176/appi.focus.23021011 · Cited by 93 · see citing works
Self-citationDrug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
Sarparast, A., Thomas, K., Malcolm, B., & Stauffer, C. S. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06083-y · Cited by 88 · see citing works
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 85 · see citing works
Oehen, P., & Gasser, P. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.863552 · Cited by 73 · see citing works
“On one hand, short-term tapering as we used in our method, has been shown to diminish response to MDMA-assisted therapy (36).”
MethodReview of otential sychedelic reatments for PTSD
Henner, R. L., Keshavan, M. S., & Hill, K. P. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120302 · Cited by 49 · see citing works
Vizeli, P., Straumann, I., Duthaler, U., Varghese, N., Eckert, A., Paulus, M. P., Risbrough, V. B., & Liechti, M. E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.906639 · Cited by 47 · see citing works
“A recent study has suggested that exposure to antidepressant drugs could decrease the treatment responsiveness toMDMA in psychotherapy (Feduccia et al., 2020).”
BackgroundThe need for establishing best practices and gold standards in psychedelic medicine
Feduccia, A. A., Agin-Liebes, G., Price, C. M., Grinsell, N., Paradise, S., & Rabin, D. M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.083 · Cited by 43 · see citing works
Self-citationLiechti, M. E., & Holze, F. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_270 · Cited by 35 · see citing works
Erritzøe, D., Barba, T., Spriggs, M. J., Rosas, F. E., Nutt, D., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241237870 · Cited by 33 · see citing works
“…antidepressant medications (versus no immediate prior use of such medications) had a negative impact on study outcomes in the treatment of post-traumatic stress disorder (PTSD) – meaning that those who were unmedicated before the start of the trial responded better to MDMA (Feduccia et al., 2021).”
BackgroundPsychedelic-Assisted Therapy for People with Eating Disorders
Gukasyan, N., Schreyer, C. C., Griffiths, R. R., & Guarda, Á. S. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01394-5 · Cited by 31 · see citing works
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Baker, P., Bruno, R., Wenge, T., & Bright, S. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221127954 · Cited by 24 · see citing works
“Evidence from recent clinical trials using substance-assisted psychotherapy (SAPT) provides preliminary evidence for the safety and efficacy for using some psychoactive substances in combination with psychological support and/or psychotherapeutic interventions for treatment refractory post-traumatic stress disorder (P…”
BackgroundKruger, D. J., Aday, J. S., Fields, C. W., Kolbman, N., Glynos, N. G., Barron, J., Herberholz, M., & Boehnke, K. F. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0011 · Cited by 22 · see citing works
Marchetta, E., Mancini, G. F., Morena, M., & Campolongo, P. (2022) · Current Neuropharmacology · doi:10.2174/1570159x21666221207162750 · Cited by 17 · see citing works
MDMA-assisted psychotherapy for post-traumatic stress disorder: The devil is in the detail
Bedi, G., Cotton, S. M., Guerin, A. A., & Jackson, H. J. (2022) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674221127186 · Cited by 18 · see citing works
Price, C. M., Feduccia, A. A., & DeBonis, K. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001595 · Cited by 17 · see citing works
Self-citationCarhart-Harris, R. L., Blemings, A., & Nutt, D. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2108082 · Cited by 15 · see citing works
FDA rejects ecstasy as a therapy: what’s next for psychedelics?
Reardon, S. (2024) · Nature · doi:10.1038/d41586-024-02597-x · Cited by 15 · see citing works
Cardiovascular and temperature adverse actions of stimulants
Docherty, J. R., & Alsufyani, H. A. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15465 · Cited by 13 · see citing works
“Interestingly, patients who had discontinued anti-depressants had a diminished clinical response to MDMA and lesser rises in blood pressure than those who had not been treated with anti-depressants (Feduccia et al., 2021).”
BackgroundInfluentialPerioperative Considerations for Patients Exposed to Psychostimulants
Emerick, T. D., Martin, T. J., & Ririe, D. G. (2023) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006303 · Cited by 12 · see citing works
Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activity
Warner‐Schmidt, J. L., Pittenger, C., Stogniew, M., Mandell, B., Olmstead, S. J., & Kelmendi, B. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1041277 · Cited by 11 · see citing works
Challenges in translational research: MDMA in the laboratory versus therapeutic settings
de Wit, H., Bershad, A. K., & Grob, C. S. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211015221 · Cited by 11 · see citing works
Interventions to help patients withdraw from depression drugs: A systematic review
Gøtzsche, P. C., & Demasi, M. (2023) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-230011 · Cited by 12 · see citing works
Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA
Warner‐Schmidt, J. L., Stogniew, M., Mandell, B., Rowland, R. S., Schmidt, E. F., & Kelmendi, B. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1353131 · Cited by 6 · see citing works
Psychedelic-Assisted Therapy for Social Adaptability in Autistic Adults
Danforth, A. L. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_269 · Cited by 5 · see citing works
Neuroimaging and the Investigation of Drug-Drug Interactions Involving Psychedelics
Wall, M. B., Harding, R., Ertl, N., Barba, T., Zafar, R. R., Sweeney, M., Nutt, D., Rabiner, E. A., & Erritzøe, D. (2024) · Neuroscience Insights · doi:10.1177/26331055241286518 · Cited by 3 · see citing works
Chou, D., Peng, H., Lin, T., Hsieh, M., Lai, C., & Lee, C. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111201 · Cited by 3 · see citing works
Drug and MDMA Interactions Implications for Public Health
Papaseit, E., Farré, M., & Pérez‐Mañá, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-92392-1_121 · Cited by 1 · see citing works
Serotonergic antidepressant use is associated with weaker psilocybin effectsPreprint
Gukasyan, N., Griffiths, R. R., Yaden, D. B., Antoine, D. G., & Nayak, S. M. (2022) · doi:10.31234/osf.io/2zys9 · Cited by 1 · see citing works
Drug and MDMA Interactions Implications for Public Health
Papaseit, E., Farré, M., & Pérez‐Mañá, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-67928-6_121-1
Risks and adverse events associated with the use of psychedelics
Neill, J. C., Shahid, M., Gittins, R., Schlag, A. K., & Tarazi, F. I. (2023) · doi:10.1093/med/9780192863607.003.0010
Open MDMA: An Open Source Framework and Practical Guide for the Therapeutic use of MDMAPreprint
Groeneveld, M., & Harper, T. (2024) · doi:10.31234/osf.io/aps5g
Groeneveld, M., & Harper, T. (2024) · doi:10.31234/osf.io/aps5g_v1
MDMA-Assisted Psychotherapy Phase 3 Trial Publication Retractions
Tabaac, B. J., Muir, O. S., & Shinozuka, K. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001847
Groeneveld, M., & Harper, T. (2025) · doi:10.31234/osf.io/aps5g_v4
Green, W., Raut, S. B., James, F. L. J., Benedek, D. M., Ursano, R. J., Capaldi, V. F., & Johnson, L. R. (2026) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000478
- Authors
- Feduccia, A. A., Jerome, L., Mithoefer, M. C., & Holland, J.
- Affiliations
- Medical University of South Carolina (US)
- Corresponding author
- Feduccia, Allison A.
- Venue
- Psychopharmacology
- Published
- 2020-11-21
- Volume
- 238
- Issue
- 2
- Pages
- 581-588
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC7826309
- OpenAlex
- W3107283988
- Cited by
- 40
- References
- 39
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 10 · 2023: 7 · 2022: 12 · 2021: 8
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- retraction (2024-08-10)
- Open access
- hybrid
- doi.org
- Locations
- Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- MAPS Public Benefit Corp
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- MDMA-assisted psychotherapy, post-traumatic stress disorder, antidepressant tapering, serotonin transporter, depression severity, treatment response, blood pressure, retraction
- MeSH terms
- Drug Tapering, Adult, Antidepressive Agents, Combined Modality Therapy, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Psychotherapy, Stress Disorders, Post-Traumatic, Neurotransmitter Uptake Inhibitors, Randomized Controlled Trials as Topic, Treatment Outcome, Clinical Trials, Phase II as Topic, N-Methyl-3,4-methylenedioxyamphetamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
